Method for Diagnosing Non-Small Cell Lung Cancer
First Claim
1. A method of diagnosing non-small cell lung cancer (NSCLC) or a predisposition to developing non-small cell lung cancer in a subject, comprising determining the expression level of a non-small cell lung cancer-associated gene in a biological sample derived from the subject, wherein an increase of said expression level compared to a normal control level of said gene indicates that said subject suffers from or is at risk of developing NSCLC, wherein said NSCLC-associated gene is selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
5 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
-
Citations
68 Claims
- 1. A method of diagnosing non-small cell lung cancer (NSCLC) or a predisposition to developing non-small cell lung cancer in a subject, comprising determining the expression level of a non-small cell lung cancer-associated gene in a biological sample derived from the subject, wherein an increase of said expression level compared to a normal control level of said gene indicates that said subject suffers from or is at risk of developing NSCLC, wherein said NSCLC-associated gene is selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
-
8. A NSCLC reference expression profile, comprising a gene expression pattern of two or more genes selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
-
9. A kit comprising two or more detection reagents which detect the expression of one or more genes selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
-
10. An array comprising two or more polynucleotides which bind to one or more genes selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
-
11. A method of identifying a compound that inhibits the expression level of an NSCLC-associated gene, comprising the steps of:
-
(1) contacting a test cell expressing said NSCLC-associated gene with a test compound; (2) detecting the expression level of said NSCLC-associated gene; and (3) determining the compound that suppresses said expression level compared to a normal control level of said gene as an inhibitor of said NSCLC-associated gene wherein said NSCLC-associated gene is selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1. - View Dependent Claims (12)
-
-
13. A method of screening for a compound for treating or preventing NSCLC, said method comprising the steps of:
-
(1) contacting a test compound with a polypeptide selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1; (2) detecting the binding activity between the polypeptide and the test compound; and (3) selecting a compound that binds to the polypeptide. - View Dependent Claims (41, 63)
-
-
14. A method of screening for a compound for treating or preventing NSCLC, said method comprising the steps of:
-
(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1; (b) detecting the biological activity of the polypeptide of step (a); and (c) selecting a compound that suppresses the biological activity of the polypeptide selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1 in comparison with the biological activity detected in the absence of the test compound. - View Dependent Claims (15)
-
-
16. A method of screening for a compound for treating or preventing NSCLC, said method comprising the steps of:
-
(1) contacting a test compound with a cell expressing one or more marker genes, wherein the one or more marker genes is selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1; and (2) selecting a compound that reduces the expression level of one or more marker genes selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1. - View Dependent Claims (17)
-
-
18. A method of screening for compound for treating or preventing NSCLC, said method comprising the steps of:
-
(1) contacting a test compound with a cell into which a vector comprising the transcriptional regulatory region of one or more marker genes and a reporter gene that is expressed under the control of the transcriptional regulatory region has been introduced, wherein the one or more marker genes are selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1; (2) measuring the activity of said reporter gene; and (3) selecting a compound that reduces the expression level of said reporter gene, as compared to a control.
-
-
19. A method of screening for a compound for treating or preventing NSCLC, said method comprising the steps of:
-
(1) contacting a KIF11 polypeptide or functional equivalent thereof with KOC1 polypeptide or functional equivalent thereof in the presence of a test compound; (2) detecting the binding between the polypeptides; and (3) selecting the test compound that inhibits the binding between the polypeptides. - View Dependent Claims (20, 21)
-
-
22. A method of measuring RNA transporting activity of a polypeptide, said method comprising the steps of:
-
a. contacting a polypeptide selected from the group consisting of; i. a polypeptide comprising the amino acid sequence of SEQ ID NO;
2 (KIF11);ii. a polypeptide comprising the amino acid sequence of SEQ ID NO;
2 wherein one or more amino acids are substituted, deleted, or inserted, and said polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO;
2;iii. a polypeptide that comprises the amino acid sequence having at least about 80% homology to SEQ ID NO;
2; andiv. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO;
1, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO;
2;with a RNA to be transported and under the condition capable of RNA transporter formation; b. detecting the level of the transported RNA; and c. measuring the RNA transporting activity by correlating the level of the transported RNA of step (b) with the RNA transporting activity. - View Dependent Claims (23, 24)
-
-
25. A method identifying an agent that modulate RNA transporting activity, said method comprising the steps of:
-
a. contacting the agent with a polypeptide selected from the group consisting of; i. a polypeptide comprising the amino acid sequence of SEQ ID NO;
2 (KIF11);ii. a polypeptide comprising the amino acid sequence of SEQ ID NO;
2 wherein one or more amino acids are substituted, deleted, or inserted, and said polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO;
2;iii. a polypeptide that comprises the amino acid sequence having at least about 80% homology to SEQ ID NO;
2; andiv. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO;
1, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO;
2;with a RNA to be transported and under the condition capable of RNA transporter formation; b. detecting the level of the transported RNA; and c. comparing the level of the transported RNA to a control level in the absence of the agent wherein an increase or decrease in the level of the transported RNA compared to control level indicates that the test compound modulates RNA transporting activity.
-
-
26. A method of screening for a compound for treating or preventing NSCLC, said method comprising the steps of:
-
(1) contacting a KOC1 polypeptide, or functional equivalent thereof with a RNA in the presence of a test compound; (2) detecting the binding between the polypeptide and RNA; and (3) selecting the test compound that inhibits the binding between the polypeptide and RNA. - View Dependent Claims (27)
-
-
28. A method of screening for a compound for treating or preventing NSCLC, said method comprising the steps of:
-
(1) contacting a GHSR1b or NTSR1 polypeptide, or functional equivalent thereof with NMU in the existence of a test compound; (2) detecting the binding between the polypeptide and NMU; and (3) selecting the test compound that inhibits the binding between the polypeptide and NMU. - View Dependent Claims (29, 30)
-
-
31. A kit for detecting for an activity of a test compound to regulate RNA transporting activity, said kit comprising an isolated cell expressing the following components of a to d, and culture medium supporting the cell growth:
-
a. a polypeptide selected from the group consisting of; i. a polypeptide comprising the amino acid sequence of SEQ ID NO;
2 (KIF11);ii. a polypeptide comprising the amino acid sequence of SEQ ID NO;
2 wherein one or more amino acids are substituted, deleted, or inserted, and said polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO;
2;iii. a polypeptide that comprises the amino acid sequence having at least about 80% homology to SEQ ID NO;
2; andiv. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO;
1, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO;
2;b. a polypeptide selected from the group consisting of; i. a polypeptide comprising the amino acid sequence of SEQ ID NO;
105 (KOC1);ii. a polypeptide comprising the amino acid sequence of SEQ ID NO;
105 wherein one or more amino acids are substituted, deleted, or inserted, and said polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO;
105;iii. a polypeptide that comprises the amino acid sequence having at least about 80% homology to SEQ ID NO;
105; andiv. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO;
104, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO;
105;c. a RNA to be transported; and d. DCTN1.
-
-
32. A kit for screening for a compound for treating or preventing NSCLC, said kit comprising at least following elements:
-
a. a polypeptide selected from the group consisting of; i. a polypeptide comprising the amino acid sequence of SEQ ID NO;
105 (KOC1);ii. a polypeptide comprising the amino acid sequence of SEQ ID NO;
105 wherein one or more amino acids are substituted, deleted, or inserted, and said polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO;
105;iii. a polypeptide that comprises the amino acid sequence having at least about 80% homology to SEQ ID NO;
105;iv. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO;
104, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO;
105; andv. a polypeptide that comprises at least two KH domains and one or more RRM domain of SEQ ID NO;
105; andb. a RNA binding with said polypeptide. - View Dependent Claims (33)
-
-
34. A kit for screening for a compound for treating or preventing NSCLC, said kit comprising the components of:
-
a;
GHSR1b or NTSR1 polypeptide, or functional equivalent thereofb;
NMUc;
reagent for detecting the binding between the polypeptide and NMU.
-
-
35. A method of treating or preventing NSCLC in a subject comprising administering to said subject an antisense composition, said composition comprising a nucleotide sequence complementary to a coding sequence of a gene selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
- 36. A method of treating or preventing NSCLC in a subject comprising administering to said subject an siRNA composition comprising an siRNA, wherein said composition reduces the expression of a gene selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
-
39. A method for treating or preventing NSCLC in a subject comprising the step of administering to said subject a pharmaceutically effective amount of an antibody or fragment thereof that binds to a polypeptide encoded by a gene selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
-
40. A method of treating or preventing NSCLC in a subject comprising administering to said subject a vaccine comprising a polypeptide encoded by a gene selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1 or an immunologically active fragment of said polypeptide, or a polynucleotide encoding the polypeptide.
- 42. A method for treating or preventing NSCLC in a subject, said method comprising the step of administering a KOC1 mutant having dominant negative effect, or a polynucleotide encoding the mutant.
- 44. A double-stranded molecule comprising a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a KIF11, GHSR1b, NTSR1 or FOXM1 target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing a KIF11, GHSR1b, NTSR1 or FOXM1 gene, inhibits expression of said gene.
-
57. A vector comprising a polynucleotide comprising a combination of a sense strand nucleic acid and an antisense strand nucleic acid, wherein said sense strand nucleic acid comprises nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 32, 33, 34, 35, 36, 37, and 108, and said antisense strand nucleic acid consists of a sequence complementary to the sense strand.
- View Dependent Claims (58)
-
59. A composition for treating or preventing NSCLC, said composition comprising a pharmaceutically effective amount of an antisense polynucleotide against a gene selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
- 60. A composition for treating or preventing NSCLC, said composition comprising a pharmaceutically effective amount of an siRNA against a gene selected from the group consisting of KIF1, GHSR1b, NTSR1, and FOXM1.
-
62. A composition for treating or preventing NSCLC, said composition comprising a pharmaceutically effective amount of an antibody or fragment thereof that binds to a polypeptide encoded by a gene selected from the group consisting of KIF11, GHSR1b, NTSR1, and FOXM1.
- 64. A composition for treating or preventing NSCLC, said composition comprising a pharmaceutically effective amount of the KOC1 mutant having dominant negative effect, or a polynucleotide encoding the mutant as an active ingredient, and a pharmaceutically acceptable carrier.
-
66. A method of predicting a NSCLC prognosis, wherein the method comprises the steps of:
-
a. detecting expressing level of either or both of KIF11 and KOC1 in a specimen collected from a subject whose NSCLC prognosis is to be predicted, and b. indicating a poor prognosis when an elevation of the expressing level of either or both of KIF11 and KOC1 is detected. - View Dependent Claims (67)
-
-
68. A kit for predicting a NSCLC prognosis, wherein the kit comprising any one component select from the group consisting of:
-
(a) reagent for detecting the mRNA encoding the amino acid sequence of SEQ ID NO;
2 (KIF11) or SEQ ID NO;
105 (KOC1),(b) reagent for detecting the protein comprising the amino acid sequence of SEQ ID NO;
2 (KIF11) or SEQ ID NO;
105 (KOC1), and(c) reagent for detecting the biological activity of the protein comprising the amino acid sequence of SEQ ID NO;
2 (KIF11) or SEQ ID NO;
105 (KOC1).
-
Specification